Holen Sie sich die Stockscreener-App
40.00
25.04%
8.01
Handel nachbörslich:
39.97
-0.03
-0.08%
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - Sahm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Oruka psoriasis drug targets twice-yearly dosing in Phase 2 trials - Stock Titan
Should Oruka’s Once-Yearly ORKA-001 Psoriasis Dosing Ambition Require Action From Oruka Therapeutics (ORKA) Investors? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Published on: 2026-03-08 05:39:15 - baoquankhu1.vn
Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 17.2% in February - MarketBeat
Is Oruka Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Rallies & Smart Allocation Stock Reports - mfd.ru
Oruka Therapeutics COO Sandler sells $167,821 in shares - Investing.com
Oruka Therapeutics Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 62% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics: A Potential Future Psoriasis Play (NASDAQ:ORKA) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Holdings in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
RTW INVESTMENTS, LP Expands Stake in Oruka Therapeutics Inc - GuruFocus
How Oruka Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 71.70% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Chart Watch & Low Risk Entry Point Guides - baoquankhu1.vn
Evaluating Oruka Therapeutics (ORKA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares - MarketBeat
Big Money Moves: Whats the beta of Uniti Group Inc stockGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Summary: Is Oruka Therapeutics Incs ROE strong enoughJuly 2025 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Assessing Oruka Therapeutics (ORKA) Valuation After Recent Trading Cooldown - simplywall.st
Published on: 2026-02-15 16:13:39 - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Promising 70% Upside Potential In Biotech - DirectorsTalk Interviews
How cyclical is Oruka Therapeutics Inc.’s revenue streamJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - mfd.ru
Candriam S.C.A. Buys 250,296 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Is Oruka Therapeutics Inc. stock a contrarian buyWeekly Earnings Recap & Weekly Market Pulse Updates - mfd.ru
Will Oruka Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Accurate Buy Signal Alerts - mfd.ru
Oruka Therapeutics to Participate in Multiple Upcoming Conferences - The Manila Times
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 77% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Dow Update: What is Oruka Therapeutics Incs book value per share2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Report: Biotechnology Pioneer Poised for 57.87% Upside - DirectorsTalk Interviews
Portfolio Update: Is Global Blue Group Holding AG Equity Warrant stock a top performer YTDQuarterly Growth Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
How cyclical is Oruka Therapeutics Incs revenue streamWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Fed Meeting: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):